Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AID System Functionality and Safety in T1DM
NCT03743285Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
Open-label, single-arm trial, sponsored by Eli Lilly and Company. Primary endpoints: Number of Adverse Events (AEs) at 6 days and Continuous Glucose Monitor (CGM) Measured Percentage of Time <70 mg/dL at 6 days. Started Nov 2018; status: completed.
Beyond the preview
Go deeper on NCT03743285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03743285.